Company Overview and News
On a relative basis, Biotechs represent a good opportunity as the sector remains ~20% below its all-time high. (617-6)
* FDA lifts clinical hold on cellectis phase 1 clinical trials with UCART123 in AML and BPDCN (6-0)
Juno Therapeutics Inc (NASDAQ:JUNO), which is a biotech operator that is focused on cancer treatments, has seen its stock languish during September. Yet this has come after a blistering performance. From early June, JUNO stock has logged a return of over 80%. (125-1)
The Biotechnology sector remains one of the top performing sectors this year with the benchmark Nasdaq Biotechnology Index, as represented by ETF (IBB), gaining 17% in the first-half. The index though still remains ~29% down from its all-time high achieved in mid-2015. In comparison, the S&P 500 (SPY) was up 8%, and the Nasdaq Composite (QQQ) up 14%, in the first-half.
Agenus Inc (AGEN - Free Report) : This immuno-oncology (I-O) company has witnessed the Zacks Consensus Estimate for its current year earnings surging 10.2% over the last 30 days.
RnRMarketResearch.com adds "Myelodysplastic Syndrome Pipeline Review H1 2017" therapeutic market research report provides an overview of the Myelodysplastic Syndrome's therapeutic pipeline.
In 2016, almost 500 private biotech companies successfully fundraised, and nearly two dozen young biotech completed IPOs.
The latest disease pipeline guide Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Pipeline Review, H1 2017, provides an overview of the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline landscape. Past infection with the Epstein-Barr virus (EBV) and HIV infection are at increased risk compared to the general population. Treatment includes surgery, radiation therapy and chemotherapy.
As of late, it has definitely been a great time to be an investor in Cellectis SA (CLLS - Free Report) . The stock has moved higher by 11% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path.
Pfizer Inc. (NYSE:PFE) is one of the world's largest pharmaceutical firms with sales exceeding $50 billion. The company is currently attractively valued at a blended P/E ratio of 13.3, offering a current dividend yield of 4%. Pfizer is awarded an S&P credit rating of AA and possesses a modest debt to capital ratio of 28%.
* Cellectis SA says first patient treated in phase 1 trial of ucart19 in pediatric acute B lymphoblastic leukemia
LONDON (Reuters) - A second baby with aggressive leukemia has been treated in London with "designer immune cells" developed by Cellectis and, six months after treatment, she remains in remission, the French biotech firm said on Friday.
LONDON: A second baby with aggressive leukemia has been treated in London with "designer immune cells" developed by Cellectis and, six months after treatment, she remains in remission, the French biotech firm said on Friday.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: February, 2016 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter) 8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual
Exhibit Exhibit 99.1 Joint Filing Agreement Pursuant to Rule 13d-1 This agreement is made pursuant to Rule 13d-l(k)(1) under the Securities and Exchange Act of 1934, as amended (the “Act”) by and among the parties listed below, each referenced to herein as a “Joint Filer.” The Joint Filers agree that a statement of beneficial ownership as required by Sections 13(g) or 13(d) of the Act and the Rules thereunder may be filed on each of their behalf on Schedule 1
2017-12-11 - Wilton
2017-12-11 - Wilton
2017-12-03 - Wilton
2017-11-27 - Wilton